ArticleCancer medicine2025
Attribute Preferences for Somatostatin Analogues in Neuroendocrine Tumours (NETs) Among Patients, Clinicians and Nurses in Australia.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundLong-acting somatostatin analogues (LA SSAs) are commonly used as first-line treatment in well-differentiated low and intermediate grade 1-2 gastroenteropancreatic neuroendocrine tumours (GEP-NETs). As a long-term treatment option for NETs, treatment preferences should be taken into consideration. The objective of this study is to evaluate the relative importance of different LA SSA treatment features among patients with NETs, clinicians and nurses in Australia.
methodsA discrete choice experiment (DCE) method was used to analyse treatment preferences for NETs, embedded in an online survey. Participants could choose between three hypothetical treatment options: 'deep subcutaneous injectable treatment', 'deep intramuscular injectable treatment', 'oral treatment'; and an opt-out. Each option was described by seven attributes: 'Progression free survival' (PFS), 'symptom control for diarrhoea and flushing', 'risk of gastrointestinal (GI) side effects', 'frequency of administration', 'treatment administration,' 'treatment delivery,' and 'availability of patient support'. A Mixed Multinomial Logit model (MMNL) was used for analysis.
resultsA total of 54 patients with NETs, 27 clinicians, and 9 nurses completed the DCE (of 33, 26 and 20 planned respectively). The statistical model showed an overall preference for oral administration. 'PFS' was the most important attribute, followed by 'symptom control for diarrhoea and flushing' and 'risk of GI side effects'. 'PFS' and 'symptom control for diarrhoea and flushing' were also found to be more important to healthcare professionals (HCPs, i.e., clinicians and nurses) than patients with NETs, while the attributes 'symptom control for diarrhoea and flushing' and 'risk of GI side effects' were found to be more important in non-metropolitan areas (vs. metropolitan areas).
conclusionsAnalysis showed how patients with NETs and HCPs prioritise treatment attributes for NETs differently. Because the duration of use of LA SSA for the treatment of NETs is often long, these differences highlight the importance of involving the patient when making treatment decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.